Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>Kim A. Reiss, Susan M. Domchek, Thomas B. Karasic et al.|Journal of Clinical Oncology|2021Cited by 238
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M. Wattenberg, Kim A. Reiss, Daniella Asch et al.|British Journal of Cancer|2019Cited by 206
Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targetsMax M. Wattenberg, James W. Hodge|British Journal of Cancer|2014Cited by 27